<DOC>
	<DOCNO>NCT02687269</DOCNO>
	<brief_summary>Despite surgical medical innovation reduce mortality rate cardiac surgery , disease severity operative procedural complexity increase morbidity rate still high . Ischemia-reperfusion ( I/R ) injury , redefine cardiac surgery `` post-cardioplegic injury '' ( 2 ) whole ischemia-reperfusion , cardiopulmonary bypass surgical trauma , recognize significant contributor mortality morbidity . I/R injury classify reversible irreversible . Reversible injury include arrhythmia , edema , vascular dysfunction contractile stun express low output syndrome without cell death without apparent sign infarction serum injury marker . Irreversible reperfusion injury include apoptosis necrosis . I/R injury complex process associate increase radical , oxidant cytokine production , complement neutrophil activation endothelial activation lead microvascular dysfunction deterioration coronary flow reserve . In hypoxic heart increase anaerobic lactate production , K+ efflux membrane depolarization . The intracellular Na+ concentration rise consequence slow Na+ channel inactivation induction voltage-gated Na+ channel late current component ( late INA ) . Intracellular Na++ accumulation enhance activity reversed-mode Na+-Ca++ exchanger cause intracellular Ca++ overload ventricular dysfunction . Therefore inhibition late INA show cardioprotective . Ranolazine , FDA-approval antianginal anti-ischemic agent , high selective blocker late INA , inhibit late sodium current myocardial ischemia , decrease Na+ Ca2+ overload improve leave ventricular function experimental animal model . For reason also adjuncted cardioplegia improve diastolic function isolate Langerdoff-perfused rat heart . The author test hypothesis ranolazine improve myocardical protection patient undergo coronary artery surgery cardiopulmonary by-pass ( CPB ) .</brief_summary>
	<brief_title>Ranolazine Potential New Therapeutic Application</brief_title>
	<detailed_description>We aim perform prospective , single-center , investigator-initiated , randomize ( 1:1 ) , blind , placebo-controlled study . The patient undergoing elective complete CABG revascularization perform surgeon , randomize two different group receive , three day surgery , Ranolazine dose 375 mg twice daily placebo . After enrollement research accord inclusion exclusion criterion , randomization list computer-generated . The study participant , reserchers responsible data report analysis ecocardiographers blind treatment patient receive . In previous phase data recruitment consider registered surgery : basic clinical parameter ( age , gender , height , weight , body surface , systolic blood pressure diastolic blood pressure , mean heart rate ) ; medical history ( diabetes mellitus type I II , smoke status , chronic obstructive pulmonary desease , systemic arterial hypertension , dyslipidemia , family history cardiovascular event , angina , percutaneous coronary intervention ( PCI ) , acute myocardial infarction ( AMI ) , previous cardiac surgery , chronic peripheral arterial disease , cerebral ischemia , bleed chronic renal failure ) ; basic hematologic parameter ( creatinine , glucose , hemoglobin , hematocrit , white blood cell count equation , platelet number , aPTT , INR ) ; baseline transthoracic echocardiographic ( TTE ) parameter ( leave ventricular ejection function ( LVEF ) , leave ventricular volume , leave ventricular regional wall motion , diastolic function ( mitral inflow velocity Early diastolic velocity ( E ) , late diastolic velocity atrial contraction ( A ) , deceleration time ( DT ) , early diastolic velocity ( e ' ) late diastolic velocity atrial contraction ( ' ) use tissue Doppler imaging , pulmonary artery systolic pressure ( PASP ) , valvulopathy aortic desease ) ; assestment risk stratification accord different score ( New York Heart Association ( NYHA ) class , Canadian Cardiovascular Society ( CCS ) Angina grade scale , EUROSCORE II , American Society og Anesthesiologists ( ASA ) physical status classification system ) ; preoperative patient therapy . In follow phase laboratory , hemodynamic imaging evaluation carry subsequent CABG surgery . Through coronary sinus insert catheter dose Troponine I ( TnI ) immediately CPB release aortic cross clamp , 10 minute end reperfusion . TnI also dose arrival intensive care unit 6 , 12 , 24 , 48 h unclamping aorta . Blood sample collect simultaneously radial artery coronary sinus start CPB removal aortic cross clamp evaluate lactate extraction , oxygen consumption ( VO2 ) oxygen extraction ( O2ER ) , C-reactive protein ( CRP ) pre post-CPB . Hemodynamic measurement obtain arterial pulmonary artery catheter ( PAC ) insert surgery , include arterial pressure ( systolic , diastolic mean pressure ) , pulmonary artery pressure ( PAP ) , right atrial pressure ( RAP ) , pulmonary artery wedge pressure ( PAWP ) , cardiac output ( CO ) cardiac index ( CI ) , systemic vascular resistance ( SVR ) , leave ventricular stroke work ( LVSW ) , leave stroke volume variaton ( LSVV ) coronary artery perfusion pressure ( CPP ) ; measurement conduct 30 min intubation , sternotomy , 10 min protamin , sternosynthesis , arrival intensive care unit , 6 , 12 , 24 , 36 , 48 h CPB . Lastly transesophageal echocardiographic study perform two expert echocardiographers follow protocol Society Cardiovascular Anesthesiologists ( 21 ) American Society Echocardiography ( 22 ) . Left ventricle myocardial performance index , LVEF , leave ventricular regional wall motion , E/A ratio , E ' , E/E ' deceleration time ( DT ) mitral inflow velocity measure ; measurement obteined 30 minute intubation sternotomy ten minute protamin . All collect data enter database Excel format .</detailed_description>
	<mesh_term>Myocardial Stunning</mesh_term>
	<mesh_term>Ranolazine</mesh_term>
	<criteria>age ≥ 18 year sinus rhythm , heart rate ( FC ) ≥ 50 bpm rest ; NYHA class I , II , III ( CCS I , II , III ) ; drug intolerance hypersensitivity ; cardiogenic shock ; ejection fraction ( FE ) ≤ 50 % ; NYHA class IV ( CCS IV ) ; II III atrioventricular block ; rest heart rate ( HR ) &lt; 50 bpm sick sinus syndrome ; ratecorrected QT interval ( QTc ) great 500 m ; age &lt; 18 year ; symptomatic hypotension uncontrolled hypertension ( systolic blood pressure rest ≥ 180 mmHg diastolic blood pressure ≥ 100 mmHg ) ; severe liver disease severe renal impairment ( creatinine clearance ≤ 30 ml/min ) ; moderate severe electrolyte disorder ( potassium concentration &lt; 2,5 &gt; 6 mmol/L ; calcium concentration &lt; 8 &gt; 11 mg/dl ; magnesium &lt; 1,8 &gt; 2,5 mg/dl ) ; pregnancy ; concomitant administration potent CYP3A4 inhibitor ( e.g . itraconazole , ketoconazole , voriconazole , posaconazole , HIV protease inhibitor , clarithromycin , telithromycin , nefazodone ) concomitant administration Class Ia ( e.g . quinidine ) Class III ( e.g . dofetilide , sotalol ) antiarrhythmics amiodarone ; previous cardiac intervention</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>myocardial protection</keyword>
	<keyword>coronary artery bypass grafting</keyword>
</DOC>